LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Highly Accurate Test "Fishes" For Respiratory Viruses Using DNA as Bait

By LabMedica International staff writers
Posted on 17 Jan 2023
A new test uses DNA ‘nanobait’ to detect common respiratory viruses (Photo courtesy of Pexels)
A new test uses DNA ‘nanobait’ to detect common respiratory viruses (Photo courtesy of Pexels)

Following the arrival of the winter cold, flu and RSV season in the northern hemisphere, healthcare workers are required to take quick decisions about the treatment to be given to patients presenting themselves at hospitals or clinics. PCR (polymerase chain reaction) tests are highly specific and accurate, but are capable of testing for only a single virus at a time and return results after several hours. Now, a new test uses single strands of DNA as ‘bait’ to ‘fish’ for multiple respiratory viruses at once and delivers accurate results in less than an hour.

The new test developed by researchers at University of Cambridge (Cambridge, UK) uses DNA ‘nanobait’ to detect common respiratory viruses – including influenza, rhinovirus, RSV and COVID-19 – simultaneously. Many of the common respiratory viruses have similar symptoms, but need different treatments. The new approach tests for multiple viruses at once, allowing the right treatment to be administered quickly to the patients and minimizing the unwarranted use of antibiotics. Additionally, it is possible for healthcare workers to use the test in any setting, and it can also be easily modified to detect different bacteria and viruses, including future SARS-CoV-2 variants.

While PCR tests are powerful, sensitive and accurate, they require a piece of genome to be copied millions of times – a process that can take several hours. The researchers set out to develop a test that uses RNA to detect viruses directly without the need for copying the genome, but had sufficiently high sensitivity for use in a healthcare setting. The team developed the test based on structures built from double strands of DNA with overhanging single strands. These single strands act as the ‘bait’ meaning they are programmed to ‘fish’ for specific regions in the RNA of target viruses. The nanobaits are then passed through very tiny holes called nanopores. Nanopore sensing is similar to a ticker tape reader that transforms molecular structures into digital information within milliseconds. Each nanobait’s structure reveals the target virus or its variant. The researchers demonstrated that it is possible to easily reprogram the test to allow it to discriminate between viral variants, including SARS-CoV-2 variants. The precision of the programmable nanobait structures allows the approach to offer almost 100% specificity.

“Good diagnostics are the key to good treatments,” said Filip Bošković from Cambridge’s Cavendish Laboratory. “People show up at hospital in need of treatment and they might be carrying multiple different viruses, but unless you can discriminate between different viruses, there is a risk patients could receive incorrect treatment.”

“For patients, we know that rapid diagnosis improves their outcome, so being able to detect the infectious agent quickly could save their life,” said co-author Professor Stephen Baker, from the Cambridge Institute of Therapeutic Immunology and Infectious Disease. “For healthcare workers, such a test could be used anywhere, in the UK or in any low- or middle-income setting, which helps ensure patients get the correct treatment quickly and reduce the use of unwarranted antibiotics.”

Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Urine Chemistry Control
Dropper Urine Chemistry Control

Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more